Quick Answer
PLUS THERAPEUTICS, INC. reported Operating Income of -$15.30 million for fiscal year 2025.
PLUS THERAPEUTICS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$15.30M | -4.1% |
| 2024 | -$14.70M | -10.3% |
| 2023 | -$13.32M | +32.4% |
| 2022 | -$19.71M | -57.8% |
| 2021 | -$12.49M | -30.3% |
| 2020 | -$9.58M | -162.1% |
| 2019 | -$3.66M | +58.3% |
| 2018 | -$8.76M | +57.6% |
| 2017 | -$20.68M | -5.0% |
| 2016 | -$19.71M | -28.9% |
| 2015 | -$15.29M | +52.9% |
| 2014 | -$32.44M | -5.7% |
| 2013 | -$30.68M | -8.0% |
| 2012 | -$28.42M | +3.4% |
| 2011 | -$29.41M | -16.1% |
| 2010 | -$25.32M | -17.5% |
| 2009 | -$21.55M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.48M | -18.0% | -191.4% |
| June 30, 2025 | -$1.54M | +58.4% | +56.5% |
| March 31, 2025 | -$3.54M | -7.2% | +6.9% |
| September 30, 2024 | -$3.80M | -16.9% | -2.8% |
| June 30, 2024 | -$3.70M | -148.1% | -12.1% |
| March 31, 2024 | -$3.30M | +30.1% | -1.5% |
| September 30, 2023 | -$3.25M | +36.2% | -118.2% |
| June 30, 2023 | -$1.49M | +70.9% | +68.4% |
- PLUS THERAPEUTICS, INC. showed a decrease of -4.1% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, PLUS THERAPEUTICS, INC.’s operating income has grown by 29.0% (from -$21.55 million to -$15.30 million).
- The most recent figure is from PLUS THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: